Avery Love
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Avery Love has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Afaq Motiwala
Department of Cardiology, University of Texas Medical Branch, Galveston, Texas, USA
1 shared publicationAiham Albaeni
Department of Cardiology, University of Texas Medical Branch, Galveston, Texas, USA
1 shared publicationAlexander Bosley
Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA
1 shared publication- Chandler O'LEary
Center for Phage Technology, Texas A&M University, College Station, Texas, USA
1 shared publication Khalil Anouti
Department of Cardiology, University of Texas Medical Branch, Galveston, Texas, USA
1 shared publicationPeter Rasmussen
Department of Cardiology, University of Texas Medical Branch, Galveston, Texas, USA
1 shared publication
Latest Publications
- Open Access
- 18 October 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (37) , 105756
Non-ST-Segment Elevation Myocardial Infarction Secondary to Embolic Prosthetic Valve Thrombus
- 18 October 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (37) , 105756
Open AccessNon-ST-Segment Elevation Myocardial Infarction Secondary to Embolic Prosthetic Valve Thrombus
- Open Access
- 21 August 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (24) , 104756
Coronary Artery Supply to a Cardiac Mass
- 21 August 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (24) , 104756
Open AccessCoronary Artery Supply to a Cardiac Mass
- Open Access
- 1 June 2025
- Published by SAGE Publications in Clinical Medicine Insights: Cardiology
- Vol. 19
Coronary Revascularization in the Era of TAVR: Timing, Strategy, and Outcomes
Background: Coronary artery disease (CAD) is prevalent among patients undergoing transcatheter aortic valve replacement (TAVR), complicating clinical decision-making regarding optimal timing of percutaneous coronary intervention (PCI). Despite widespread clinical experience, there is ongoing controversy and limited consensus regarding when PCI, before, during, or after TAVR, offers the best risk-benefit balance. Objective: To synthesize and critically evaluate the current evidence on different PCI timing strategies in patients undergoing TAVR and to identify areas of uncertainty and clinical complexity. Review: Randomized trials, including ACTIVATION and NOTION-3, have yielded mixed findings, highlighting a modest reduction in ischemic events with pre-TAVR PCI but increased procedural bleeding risks. Observational registries (REVASC-TAVI and the National Readmissions Database) have similarly shown that pre- and peri-TAVR PCI strategies carry heightened risks of complications without clear long-term mortality benefits. Recent meta-analyses reinforce these findings, indicating that no PCI timing strategy conclusively outperforms others in reducing long-term mortality. Key considerations such as anatomical complexity, frailty, bleeding risk, and valve type significantly influence optimal PCI timing. Conclusion: Current evidence supports a personalized, patient-centered approach to PCI timing in TAVR candidates, emphasizing careful consideration of individual anatomical and clinical factors rather than a standardized timing protocol. Further research exploring advanced risk stratification, imaging modalities, and long-term clinical outcomes is essential to refine current guidelines and practice.
- 1 June 2025
- Published by SAGE Publications in Clinical Medicine Insights: Cardiology
- Vol. 19
Open AccessCoronary Revascularization in the Era of TAVR: Timing, Strategy, and Outcomes
Background: Coronary artery disease (CAD) is prevalent among patients undergoing transcatheter aortic valve replacement (TAVR), complicating clinical decision-making regarding optimal timing of percutaneous coronary intervention (PCI). Despite widespread clinical experience, there is ongoing controversy and limited consensus regarding when PCI, before, during, or after TAVR, offers the best risk-benefit balance. Objective: To synthesize and critically evaluate the current evidence on different PCI timing strategies in patients undergoing TAVR and to identify areas of uncertainty and clinical complexity. Review: Randomized trials, including ACTIVATION and NOTION-3, have yielded mixed findings, highlighting a modest reduction in ischemic events with pre-TAVR PCI but increased procedural bleeding risks. Observational registries (REVASC-TAVI and the National Readmissions Database) have similarly shown that pre- and peri-TAVR PCI strategies carry heightened risks of complications without clear long-term mortality benefits. Recent meta-analyses reinforce these findings, indicating that no PCI timing strategy conclusively outperforms others in reducing long-term mortality. Key considerations such as anatomical complexity, frailty, bleeding risk, and valve type significantly influence optimal PCI timing. Conclusion: Current evidence supports a personalized, patient-centered approach to PCI timing in TAVR candidates, emphasizing careful consideration of individual anatomical and clinical factors rather than a standardized timing protocol. Further research exploring advanced risk stratification, imaging modalities, and long-term clinical outcomes is essential to refine current guidelines and practice.